ION 224
Alternative Names: ION-224; IONIS-DGAT2Rx; ISIS 484137; ISIS-DGAT2RxLatest Information Update: 19 Mar 2024
Price :
$50 *
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antisense oligonucleotides; Hepatoprotectants
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 13 Mar 2024 Efficacy and adverse event data from phase II trial in Non-alcoholic steatohepatitis released by Ionis Pharmaceuticals
- 28 Feb 2024 Ionis Pharmaceuticals completes a phase-II trial in Non-alcoholic steatohepatitis (In adults, In the elderly) in USA and Puerto Rico (SC, Injection) (NCT04932512)
- 01 Jul 2021 Phase-II clinical trials in Non-alcoholic steatohepatitis (In adults, In elderly) in USA (SC) (NCT04932512)